Docetaxel
- Generic Name
- Docetaxel
- Brand Names
- Taxotere, Docetaxel Accord, Docetaxel Kabi
- Drug Type
- Small Molecule
- Chemical Formula
- C43H53NO14
- CAS Number
- 114977-28-5
- Unique Ingredient Identifier
- 699121PHCA
- Background
Docetaxel is a clinically well established anti-mitotic chemotherapy medication used for the treatment of different types of cancer, including breast, ovarian, and non-small cell lung cancer. Docetaxel is a complex diterpenoid molecule and a semisynthetic analogue of paclitaxel. Docetaxel reversibly binds to microtubulin with high affinity in a 1:1 stoichiom...
- Indication
Docetaxel is indicated as a single agent for the treatment of locally advanced or metastatic breast cancer after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC. It is also indicated as a single agent for locally advanced or metastatic non-small cell lung cancer (NSCLC) after platinum therapy...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Locally Advanced Breast Cancer (LABC), Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Node Positive Breast Cancer, Ovarian Cancer Metastatic, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Advanced untreated gastric adenocarcinoma, Locally advanced Squamous cell carcinoma of head and neck, Locally advanced untreated non small cell lung cancer, Metastatic untreated non small cell lung cancer, Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer, Refractory, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Bevacizumab and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 27
- Registration Number
- NCT00055861
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
- Conditions
- Recurrent Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00055770
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 413
- Registration Number
- NCT00055731
- Locations
- 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷Hopital Saint Andre, Bordeaux, France
🇫🇷Institut Bergonie, Bordeaux, France
Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 3010
- Registration Number
- NCT00054587
- Locations
- 🇫🇷
Centre Hospitalier de Mulhouse, Mulhouse, France
🇫🇷Institut Prive de Cancerologie, Grenoble, France
🇫🇷Centre Paul Papin, Angers, France
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00054054
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 46
- Registration Number
- NCT00054457
- Locations
- 🇺🇸
Associates in Womens Health, PA - North Review, Wichita, Kansas, United States
🇺🇸Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States
🇺🇸Cancer Center of Kansas, PA - Winfield, Winfield, Kansas, United States
Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00053911
- Locations
- 🇫🇷
Clinique Claude Bernard, Albi, France
🇫🇷Institut Bergonie, Bordeaux, France
🇫🇷Centre Paul Papin, Angers, France
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2020-10-05
- Lead Sponsor
- CTI BioPharma
- Target Recruit Count
- 350
- Registration Number
- NCT00054184
- Locations
- 🇺🇸
Saint Joseph Oncology, Incorporated, Saint Joseph, Missouri, United States
🇺🇸Gabrail Cancer Center - Canton Office, Canton, Ohio, United States
🇺🇸Montana Cancer Specialists, Missoula, Montana, United States
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Paula Silverman, MD
- Target Recruit Count
- 39
- Registration Number
- NCT00054275
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Docetaxel in Treating Patients With Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Target Recruit Count
- 200
- Registration Number
- NCT00022022
- Locations
- 🇮🇹
Istituto Di Ricovero E Cura A Carattere Scientifico, Bari, Italy
🇮🇹Ospedale San Paolo, Milano, Italy
🇮🇹Ospedale Luigi Sacco, Milan, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.